Article information
Abstract
The present article is an update of the literature on endocarditis. A multidisciplinary group of Spanish physicians with an interest in cardiac infections selected the most important papers produced lately in the field. Two of the members of the group discussed the content of each of the selected papers, with a critical review by others members of the panel. After a review of the state of the art papers from the fields of epidemiology, new causative microorganisms (bacterial and fungal), clinical findings including those in special patients, laboratory diagnosis, prognostic factors, nosocomial endocarditis, prophylaxis, new drugs and guidelines for antibiotic treatment were discussed by the group.
Keywords:
Endocarditis
Epidemiology
Diagnosis
Treatment
Prophylaxis
Prognostic factors
Nosocomial endocarditis
Resumen
Este artículo resume una actualización bibliográfica de las novedades más destacables de la endocarditis bacteriana. Un grupo multidisciplinario de médicos españoles con experiencia en las infecciones cardíacas seleccionó las publicaciones más importantes en este campo aparecidas recientemente en la bibliografía. El contenido de cada uno de los artículos seleccionados fue expuesto y discutido por 2 de los miembros del grupo, después del cual los miembros restantes efectuaron una revisión crítica. Después de la revisión, el grupo discutió las publicaciones sobre la epidemiología, los microorganismos causales poco frecuentes, el diagnóstico de laboratorio, la presentación en pacientes con problemas especiales, los factores pronósticos, la endocarditis nosocomial, la profilaxis antibiótica y las nuevas guías de tratamiento antibiótico, así como la utilización de nuevos antibióticos.
Palabras clave:
Endocarditis
Diagnóstico
Tratamiento
Profilaxis
Factores pronósticos
Endocarditis nosocomial
Full text is only aviable in PDF
References
[2.]
T.M. Bashore, C. Cabell, V Fowler Jr.
Update on infective endocarditis.
Curr Probl Cardiol, 31 (2006), pp. 274-352
[3.]
E. Bouza, A. Menasalvas, P. Muñoz, F.J. Vasallo, M. Del Mar Moreno, M.A. García Fernández.
Infective endocarditis--a prospective study at the end of the twentieth century: new predisposing conditions, new etiologic agents, and still a high mortality.
Medicine (Baltimore), 80 (2001), pp. 298-307
[4.]
I.M. Tleyjeh, A. Abdel-Latif, H. Rahbi, C.G. Scott, K.R. Bailey, J.M. Steckelberg, et al.
A systematic review of population-based studies of infective endocarditis.
Chest, 132 (2007), pp. 1025-1035
[5.]
E. Mylonakis, S.B. Calderwood.
Infective endocarditis in adults.
N Engl J Med, 345 (2001), pp. 1318-1330
[6.]
P. Moreillon, Y.A. Que.
Infective endocarditis.
Lancet, 363 (2004), pp. 139-149
[7.]
Hl. Cooper, J.E. Brady, D. Ciccarone, B. Tempalski, K. Gostnell, S.R. Friedman.
Nationwide increase in the number of hospitalizations for illicit injection drug use-related infective endocarditis.
Clin Infect Dis, 45 (2007), pp. 1200-1203
[8.]
F.G. De Rosa, S. Cicalini, F. Canta, S. Audagnotto, E. Cecchi, G. Di Perri.
Infective endocarditis in intravenous drug users from Italy: The increasing importance in HIV-infected patients.
Infection, 35 (2007), pp. 154-160
[9.]
E.E. Hill, S. Vanderschueren, J. Verhaegen, P. Herijgers, P. Claus, M.C. Herregods, et al.
Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia.
Mayo Clin Proc, 82 (2007), pp. 1165-1169
[10.]
R.B. Hsu, F.Y. Lin.
Methicillin resistance and risk factors for embolism in Staphylococcus aureus infective endocarditis.
Infect Control Hosp Epidemiol, 28 (2007), pp. 860-866
[11.]
M.l. Fernández Guerrero, A. Goyenechea, C. Verdejo, R.F. Roblas, M. De Gorgolas.
Enterococcal endocarditis on native and prosthetic valves: a review of clinical and prognostic factors with emphasis on hospital-acquired infections as a major determinant of outcome.
Medicine (Baltimore), 86 (2007), pp. 363-377
[12.]
B.D. Prendergast.
The changing face of infective endocarditis.
Heart, 92 (2006), pp. 879-885
[13.]
C.K. Naber, R. Erbel.
Infective endocarditis with negative blood cultures.
Int J Antimicrob Agents, 30 (2007), pp. S32-S36
[14.]
P. Brouqui, D. Raoult.
Endocarditis due to rare and fastidious bacteria.
Clin Microbiol Rev, 14 (2001), pp. 177-207
[15.]
C. Garzoni, V.A. Nobre, J. Garbino.
Candida parapsilosis endocarditis: a comparative review of the literature.
Eur J Clin Microbiol Infect Dis, 26 (2007), pp. 915-926
[16.]
C. Landais, F. Fenollar, F. Thuny, D. Raoult.
From acute Q fever to endocarditis: serological follow-up strategy.
Clin Infect Dis, 44 (2007), pp. 1337-1340
[17.]
T. Lalani, A.K. Person, S.S. Hedayati, L. Moore, D.R. Murdoch, B. Hoen, et al.
Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study.
Scand J Infect Dis, 39 (2007), pp. 840-848
[18.]
A.S. Werner, C.G. Cobbs, D. Kaye, E.W. Hook.
Studies on the bacteremia of bacterial endocarditis.
Jama, 202 (1967), pp. 199-203
[19.]
L.M. Baddour, W.R. Wilson, A.S. Bayer, V.G. Fowler Jr, A.F. Bolger, M.E. Levison, et al.
Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.
Circulation, 111 (2005), pp. E394-E434
[20.]
N.P. Jenkins, G. Habib, B.D. Prendergast.
Aorto-cavitary fistulae in infective endocarditis: understanding a rare complication through collaboration..
Eur Heart J, 26 (2005), pp. 213-214
[21.]
W.N. Campbell, W. Tsai, L.A. Mispireta.
Evaluation of the practice of routine culturing of native valves during valve replacement surgery.
Ann Thorac Surg, 69 (2000), pp. 548-550
[22.]
P. Houpikian, D. Raoult.
Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases.
Medicine (Baltimore), 84 (2005), pp. 162-173
[23.]
P.P. Bosshard, A. Kronenberg, R. Zbinden, C. Ruef, E.C. Bottger, M. Altwegg.
Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience.
Clin Infect Dis, 37 (2003), pp. 167-172
[24.]
V. Gauduchon, L. Chalabreysse, J. Etienne, M. Celard, Y. Benito, H. Lepidi, et al.
Molecular diagnosis of infective endocarditis by pcr amplification and direct sequencing of dna from valve tissue.
J Clin Microbiol, 41 (2003), pp. 763-766
[25.]
G. Lisby, E. Gutschik, D.T. Durack.
Molecular methods for diagnosis of infective endocarditis.
Infect Dis Clin North Am, 16 (2002), pp. 393-412
[26.]
M. Marín, P. Muñoz, M. Sánchez, M. Del Rosal, L. Alcalá, M. Rodríguez-Creixems, et al.
Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (pcr) and sequencing directly from heart valve tissue.
Medicine (Baltimore), 86 (2007), pp. 195-202
[27.]
R.W. Watkin, L.V. Harper, A.B. Vernallis, S. Lang, P.A. Lambert, A.M. Ranasinghe, et al.
Pro-inflammatory cytokines Il6, Tnf-alpha, Il1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis.
J Infect, 55 (2007), pp. 220-225
[28.]
A. Arvay, M. Lengyel.
Incidence and risk factors of prosthetic valve endocarditis.
Eur J Cardiothorac Surg, 2 (1988), pp. 340-346
[29.]
A. Wang, E. Athan, P.A. Pappas, V.G. Fowler Jr, L. Olaison, C. Pare, et al.
Contemporary clinical profile and outcome of prosthetic valve endocarditis.
Jama, 297 (2007), pp. 1354-1361
[30.]
H. Alonso-Valle, C. Fariñas-Álvarez, J.M. Bernal-Marco, J.D. García-Palomo, F. Gutiérrez-Díez, R. Martín-Durán, et al.
The changing face of prosthetic valve endocarditis at a tertiary-care hospital: 1986–2005.
Rev Esp Cardiol, 63 (2010), pp. 28-35
[31.]
M.C. Fariñas, A. Pérez-Vázquez, C. Fariñas-Álvarez, J.D. García-Palomo, J.M. Bernal, J.M. Revuelta, et al.
Risk factors of prosthetic valve endocarditis: a case-control study.
Ann Thorac Surg, 81 (2006), pp. 1284-1290
[32.]
H. Alonso-Valle, C. Fariñas-Álvarez, J.D. García-Palomo, J.M. Bernal, R. Martín-Durán, J.F. Gutiérrez Díez, et al.
Clinical course and predictors of death in prosthetic valve endocarditis over a 20-year period.
J Thorac Cardiovasc Surg, 139 (2010), pp. 887-893
[33.]
G. Habib, C. Tribouilloy, F. Thuny, R. Giorgi, A. Brahim, M. Amazouz, et al.
Prosthetic valve endocarditis: who needs surgery? A multicentre study of 104 cases.
Heart, 91 (2005), pp. 954-959
[34.]
J.A. San Román, J. López, I. Vilacosta, M. Luaces, C. Sarria, A. Revilla, et al.
Prognostic stratification of patients with left-sided endocarditis determined at admission.
Am J Med, 120 (2007), pp. E1-E7
[35.]
X. Duval, C. Leport.
Prophylaxis of infective endocarditis: current tendencies, continuing controversies.
Lancet Infect Dis, 8 (2008), pp. 225-232
[36.]
L.M. Baddour.
Prophylaxis of infective endocarditis: prevention of the perfect storm.
Int J Antimicrob Agents, 30 (2007), pp. S37-41
[37.]
N. Danchin, X. Duval, C. Leport.
Prophylaxis of infective endocarditis: French recommendations 2002.
Heart, 91 (2005), pp. 715-718
[38.]
Fk. Gould, T.S. Elliott, J. Foweraker, M. Fulford, J.D. Perry, G.J. Roberts, et al.
Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy.
J Antimicrob Chemother, 57 (2006), pp. 1035-1042
[39.]
W. Wilson, K.A. Taubert, M. Gewitz, P.B. Lockhart, L.M. Baddour, M. Levison, et al.
Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee. Council on Cardiovascular Disease in The Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group.
Circulation, 116 (2007), pp. 1736-1754
[40.]
L.G. Winston, A.F. Bolger.
Modern epidemiology, prophylaxis, and diagnosis and therapy for infective endocarditis.
Curr Cardiol Rep, 8 (2006), pp. 102-108
[41.]
D. Horstkotte, F. Follath, E. Gutschik, M. Lengyel, A. Oto, A. Pavie, et al.
Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the Task Force on Infective Endocarditis of the European Society of Cardiology.
Eur Heart J, 25 (2004), pp. 267-276
[42.]
T.S. Elliott, J. Foweraker, F.K. Gould, J.D. Perry, J.A. Sandoe.
Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society For Antimicrobial Chemotherapy.
J Antimicrob Chemother, 54 (2004), pp. 971-981
[43.]
Paul-Ehrlich-Gesellschaft Für Chemotherapie (Peg; Paul-Ehrlich-Society for Chemotherapy), Deutsche Gesellschaft Für Kardiologie, Herz-Und Kreislaufforschung (Dgk; German Society for Cardiology, Heart, and Circulatory Research). German Guidelines for the Diagnosis and Management of Infective Endocarditis. Int J Antimicrob Agents. 2007;29:643–57.
[44.]
K. Westling, E. Aufwerber, C. Ekdahl, G. Friman, B. Gardlund, I. Julander, et al.
Swedish Guidelines for Diagnosis and Treatment of Infective Endocarditis.
Scand J Infect Dis, 39 (2007), pp. 929-946
[45.]
B. Knoll, I.M. Tleyjeh, J.M. Steckelberg, W.R. Wilson, L.M. Baddour.
Infective Endocarditis due to Penicillin-Resistant Viridans Group Streptococci.
Clin Infect Dis, 44 (2007), pp. 1585-1592
[46.]
S. Fujitani, M.C. Rowlinson, W.l. George.
Penicillin G-resistant viridans group streptococcal endocarditis and interpretation of the American Heart Association’s Guidelines for the treatment of infective endocarditis.
Clin Infect Dis, 46 (2008), pp. 1064-1066
[47.]
L. Olaison, K. Schadewitz.
Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used?.
Clin Infect Dis, 34 (2002), pp. 159-166
[48.]
J. Gavaldà, P.L. Onrubia, M.T. Gómez, X. Gomis, J.L. Ramírez, O. Len, et al.
Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides.
J Antimicrob Chemother, 52 (2003), pp. 514-517
[49.]
J. Gavaldà, C. Torres, C. Tenorio, P. López, M. Zaragoza, J.A. Capdevila, et al.
Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides.
Antimicrob Agents Chemother, 43 (1999), pp. 639-646
[50.]
J. Gavaldà, O. Len, J.M. Miró, P. Muñoz, M. Montejo, A. Alarcón, et al.
Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.
Ann Intern Med, 146 (2007), pp. 574-579
[51.]
V.H. Chu, C.W. Woods, J.M. Miró, B. Hoen, C.H. Cabell, P.A. Pappas, et al.
Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis.
Clin Infect Dis, 46 (2008), pp. 232-242
[52.]
J.L. Haro, J.M. Lomas, A. Plata, J. Ruiz, J. Gálvez, J. De la Torre, et al.
Left-sided native valve endocarditis by coagulase-negative staphylococci: an emerging disease.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 263-268
[53.]
J.M. Miró, I. Anguera, C.H. Cabell, A.Y. Chen, J.A. Stafford, G.R. Corey, et al.
Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database.
Clin Infect Dis, 41 (2005), pp. 507-514
[54.]
V.G. Fowler Jr, J.M. Miró, B. Hoen, C.H. Cabell, E. Abrutyn, E. Rubinstein, et al.
Staphylococcus aureus endocarditis: a consequence of medical progress.
Jama, 293 (2005), pp. 3012-3021
[55.]
B.C. Millar, B.D. Prendergast, J.E. Moore.
Community-associated MRSA (CA-MRSA): an emerging pathogen in infective endocarditis.
J Antimicrob Chemother, 61 (2008), pp. 1-7
[56.]
C. Tsigrelis, M.D. Armstrong, N.E. Vlahakis, J.A. Batsis, L.M. Baddour.
Infective endocarditis due to community-associated methicillin-resistant Staphylococcus aureus in injection drug users may be associated with panton-valentine leukocidin-negative strains.
Scand J Infect Dis, 39 (2007), pp. 299-302
[57.]
N.Z. Haque, S.L. Davis, C.L. Manierski, D. Vager, S.M. Donabedian, M.B. Perri, et al.
Infective endocarditis caused by Usa300 methicillin-resistant Staphylococcus aureus (MRSA).
Int J Antimicrob Agents, 30 (2007), pp. 72-77
[58.]
A. Soriano, F. Marco, J.A. Martínez, E. Pisos, M. Almela, V.P. Dimova, et al.
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis, 46 (2008), pp. 193-200
[59.]
S.H. Kim, K.H. Kim, H.B. Kim, N.J. Kim, E.C. Kim, M.D. Oh, et al.
Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.
Antimicrob Agents Chemother, 52 (2008), pp. 192-197
[60.]
B. Almirante.
Bacteremia and vascular infections due to Gram-positive microorganisms: new therapeutic options.
Enferm Infecc Microbiol Clin, 26 (2008), pp. 44-52
[61.]
J.R. Lentino, M. Narita, V.L. Yu.
New antimicrobial agents as therapy for resistant Gram-positive cocci.
Eur J Clin Microbiol Infect Dis, 27 (2008), pp. 3-15
[62.]
R.C. Moellering Jr.
Current treatment options for community-acquired methicillinresistant Staphylococcus aureus infection.
Clin Infect Dis, 46 (2008), pp. 1032-1037
[63.]
B.P. Howden, P.B. Ward, P.G. Charles, T.M. Korman, A. Fuller, P. Du Cros, et al.
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
Clin Infect Dis, 38 (2004), pp. 521-528
[64.]
M.P. Oramas-Shirey, L.V. Buchanan, C.L. Dileto-Fang, C.F. Dailey, C.W. Ford, D.H. Batts, et al.
Efficacy of linezolid in a staphylococcal endocarditis rabbit model.
J Antimicrob Chemother, 47 (2001), pp. 349-352
[65.]
C.F. Dailey, C.L. Dileto-Fang, L.V. Buchanan, M.P. Oramas-Shirey, D.H. Batts, C.W. Ford, et al.
Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother, 45 (2001), pp. 2304-2308
[66.]
C. Jacqueline, E. Batard, L. Pérez, D. Boutoille, A. Hamel, J. Caillon, et al.
In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
Antimicrob Agents Chemother, 46 (2002), pp. 3706-3711
[67.]
C. Jacqueline, D. Navas, E. Batard, A.F. Miegeville, V. Le Mabecque, M.F. Kergueris, et al.
In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother, 49 (2005), pp. 45-51
[68.]
C. Jacqueline, J. Caillon, V. Le Mabecque, A.F. Miegeville, P.Y. Donnio, D. Bugnon, et al.
In vivo synergy of linezolid plus ertapenem combination in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Icaac).
American Society Of Microbiology, (1999),
[69.]
M.P. Stevens, M.B. Edmond.
Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature.
Clin Infect Dis, 41 (2005), pp. 1134-1142
[70.]
M.E. Falagas, K.G. Manta, F. Ntziora, K.Z. Vardakas.
Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.
J Antimicrob Chemother, 58 (2006), pp. 273-280
[71.]
P. Mancino, C. Ucciferri, K. Falasca, E. Pizzigallo, J. Vecchiet.
Methicillin-resistant Staphylococcus epidermidis (MRSE) endocarditis treated with linezolid.
Scand J Infect Dis, 40 (2008), pp. 67-73
[72.]
P. Muñoz, M. Rodríguez-Creixems, M. Moreno, M. Marín, V. Ramallo, E. Bouza.
Linezolid therapy for infective endocarditis.
Clin Microbiol Infect, 13 (2007), pp. 211-215
[73.]
A. Colli, R. Campodonico, T. Gherli.
Early switch from vancomycin to oral linezolid for treatment of Gram-positive heart valve endocarditis.
Ann Thorac Surg, 84 (2007), pp. 87-91
[74.]
J.R. Azanza, J. Barberan, J.A. García-Rodríguez, P. Llinares, J. Mensa, J. Picazo, et al.
Recommendations for the treatment of nosocomial infections caused by Gram-positive microorganisms.
Rev Esp Quimioter, 17 (2004), pp. 271-288
[75.]
C.F. Carpenter, H.F. Chambers.
Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens.
Clin Infect Dis, 38 (2004), pp. 994-1000
[76.]
J.N. Steenbergen, J. Alder, G.M. Thorne, F.P. Tally.
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
J Antimicrob Chemother, 55 (2005), pp. 283-288
[77.]
G. Sakoulas, G.M. Eliopoulos, J. Alder, C.T. Eliopoulos.
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother, 47 (2003), pp. 1714-1718
[78.]
L. Cantoni, M.P. Glauser, J. Bille.
Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination.
Antimicrob Agents Chemother, 34 (1990), pp. 2348-2353
[79.]
J. Vouillamoz, P. Moreillon, M. Giddey, J.M. Entenza.
Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
J Antimicrob Chemother, 58 (2006), pp. 1208-1214
[80.]
K.H. Rand, H.J. Houck.
Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother, 48 (2004), pp. 2871-2875
[81.]
K.L. Laplante, M.J. Rybak.
Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother, 48 (2004), pp. 4665-4672
[82.]
F. Caron, M.D. Kitzis, L. Gutmann, A.C. Cremieux, B. Maziere, J.M. Vallois, et al.
Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium.
Antimicrob Agents Chemother, 36 (1992), pp. 2611-2616
[83.]
M.C. Ramos, M.L. Grayson, G.M. Eliopoulos, A.S. Bayer.
Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant enterococci.
Antimicrob Agents Chemother, 36 (1992), pp. 1864-1869
[84.]
V.G. Fowler Jr, H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, M.E. Rupp, et al.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
N Engl J Med, 355 (2006), pp. 653-665
[85.]
M.E. Falagas, K.P. Giannopoulou, F. Ntziora, K.Z. Vardakas.
Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.
J Antimicrob Chemother, 60 (2007), pp. 7-19
[86.]
D.P. Levine, K.C. Lamp.
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Am J Med, 120 (2007), pp. S28-S33
[87.]
V.H. Chu, J.M. Miró, B. Hoen, C.H. Cabell, P.A. Pappas, P. Jones, et al.
Coagulase-negative staphylococcal prosthetic valve endocarditis - A contemporary update based on the international collaboration on endocarditis: prospective cohort study.
Heart, 95 (2009), pp. 570-576
[88.]
G.M. Feuchtner, P. Stolzmann, W. Dichtl, T. Schertler, J. Bonatti, H. Scheffel, et al.
Multislice computed tomography in infective endocarditis: comparison with transesophageal echocardiography and intraoperative findings.
J Am Coll Cardiol, 53 (2009), pp. 436-444
[89.]
X. Duval, B. Iung, I. Klein, E. Brochet, G. Thabut, F. Arnoult, et al.
Effect of early cerebral magnetic resonance imaging on clinical decisions in infective endocarditis: a prospective study.
Ann Intern Med, 152 (2010), pp. 497-504
[90.]
E. Durante-Mangoni, S. Bradley, C. Selton-Suty, M.F. Tripodi, B. Barsic, E. Bouza, et al.
Current features of infective endocarditis in elderly patients: results of the International Collaboration On Endocarditis Prospective Cohort Study.
Arch Intern Med, 168 (2008), pp. 2095-2103
[91.]
N. Benito, J.M. Miró, E. De Lazzari, C.H. Cabell, A. Del Río, J. Altclas, et al.
Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.
Ann Intern Med, 150 (2009), pp. 586-594
[92.]
M.A. Gerber, R.S. Baltimore, C.B. Eaton, M. Gewitz, A.H. Rowley, S.T. Shulman, et al.
Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics.
Circulation, 119 (2009), pp. 1541-1551
[93.]
D. Yung, D. Kottachchi, B. Neupane, S. Haider, M. Loeb.
Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review.
J Antimicrob Chemother, 60 (2007), pp. 921-928
[94.]
L.M. Baddour, A.E. Epstein, C.C. Erickson, B.P. Knight, M.E. Levison, P.B. Lockhart, et al.
Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association.
Circulation, 121 (2010), pp. 458-477
Copyright © 2011. Elsevier España S.L.. All rights reserved
